Navigation Links
NeurogesX Reports Fourth Quarter and Year-End 2008 Results
Date:3/20/2009

dient found in Qutenza, has completed three Phase 1 studies. The most recent of these studies was in 36 healthy volunteers to evaluate potential control formulations for use in later-stage clinical studies. The liquid formulation may address neuropathic pain conditions in areas of the skin that are difficult to target through a dermal patch application, and potentially offers similar efficacy in a shorter application time versus Qutenza. NeurogesX is currently evaluating the timing to initiate Phase 2 development of NGX-1998.

NeurogesX continues to pursue business development opportunities to advance its opioid and acetaminophen prodrugs.

  • NGX-9674 and NGX-5752, novel prodrugs of acetaminophen, have completed in vivo and in vitro preclinical studies, in which they demonstrated approximately 10 times greater solubility in water versus acetaminophen.
  • NGX-1576, a novel prodrug coupling acetaminophen to a liver protectant, has been evaluated in vitro and in vivo. Equivalent dose levels of NGX-1576 in mice produced significantly less liver toxicity than acetaminophen, while additional data demonstrated the production of equivalent plasma levels of acetaminophen.
  • NGX-6052, the most advanced molecule synthesized in NeurogesX' opioid prodrug platform, has been evaluated in proof of concept in vivo and in vitro preclinical studies for its potential to deliver therapeutic efficacy with an abuse-deterrent profile and improved side effect profile.

Conference Call Details

The Company will hold its quarterly conference call today at 9:00 a.m. ET (6:00 a.m. PT) to discuss fourth quarter and year-end 2008 results and the CHMP's positive opinion recommending E.U. approval of Qutenza for the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. NeurogesX to Present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
2. NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results
3. NeurogesX to Present at Susquehanna Financial Groups 2nd Annual SIGnificant Options in Healthcare Conference
4. NeurogesX to Present at RBC Capital Markets 2007 Healthcare Conference
5. NeurogesX to Report Third Quarter 2007 Financial Results on November 14, 2007
6. The NewsHour With Jim Lehrer Reports From South Africa on Renewed Efforts to Combat HIV/AIDS and Tuberculosis
7. Medical symposium highlights importance of case reports -- patient stories in modern medicine
8. Secova Reports Healthcare Provisions In The Stimulus Bill
9. Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports
10. Shamir Optical Industry Ltd. Reports Fourth Quarter and Year-End 2008 Results
11. China Pharma Holdings, Inc. Reports Record 2008 Year End Financial Results and Corporate Updates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... "Medical staff need better ways to provide quick ... privacy," said one of two inventors from Hialeah, Fla. ... supply caregivers with the equipment they need to do ... The Helper to make it easier to reposition a ... his or her side. It also securely stabilizes the ...
(Date:9/18/2014)... 2014 It’s been just a few short ... pending bunion splint to website visitors, but already the response ... was absolutely delighted. It is perfect and I find it ... them. THANK YOU FOR LISTENING!!!" Another user compared the ... hole used to slip to the end of my toe. ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Companies in ... refine carbon dioxide, selling it to downstream industries in ... for carbon dioxide are food and beverage manufacturers. Food ... as fruits, vegetables or pizzas. The gas is also ... use the compound to carbonate soft drinks, beer and ...
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, ... waiting times, patients seeking care at larger urban hospitals are ... those seen at smaller or more rural facilities, new research ... provide timely emergency care varies dramatically across hospitals in the ... research, Dr. Renee Hsia, an associate professor at the University ...
(Date:9/18/2014)... Sept. 18, 2014 (HealthDay News) -- Daily supplements of ... against the development of age-related cataracts among men, a ... that one or both could help prevent cataracts. To ... Hospital and Harvard Medical School in Boston, and his ... selenium and vitamin E. The trial was initially designed ...
Breaking Medicine News(10 mins):Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:ER Waiting Times Vary Significantly, Studies Find 2Health News:ER Waiting Times Vary Significantly, Studies Find 3Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2
... MONDAY, Oct. 17 (HealthDay News) -- For years, nutritionists ... eat." Now, new research suggests this adage might even ... observation stems from a pair of studies slated for presentation ... in Orlando, Fla., both of which highlight an apparent linkage ...
... MASS. October 17, 2011 The Institute for ... announced Sharon K. Inouye, M.D., M.P.H., has been elected ... independent, nonprofit organization that works outside of government to ... the public. Inouye is the Director of the ...
... HealthDay Reporter , MONDAY, Oct. 17 (HealthDay News) ... candy and some medications, teachers are almost as likely to ... by two enterprising elementary schoolers. Casey Gittelman, who,s ... a special medicine cabinet filled with medicine and candies to ...
... is available in French and Spanish . ... than other women. Furthermore, the likelihood of developing breast cancer is ... of the main conclusions drawn in an article recently published in ... Granada research group CTS 367, coordinated by the Nursery Department professor ...
... Jenifer Goodwin HealthDay Reporter , SATURDAY, Oct. 15 ... hospital emergency departments don,t believe their weight poses a risk ... them otherwise, a new study finds. Researchers asked 450 ... at Shands at the University of Florida two questions: Do ...
... HealthDay Reporter , MONDAY, Oct. 17 (HealthDay News) -- Is ... so, says a new study that finds a link between ... However, the research doesn,t confirm that exposure to trash-talking ... explain why non-aggressive cussing might be a bad thing. And ...
Cached Medicine News:Health News:Healthier Diet, Stronger Sperm? 2Health News:Healthier Diet, Stronger Sperm? 3Health News:Hebrew SeniorLife's Dr. Sharon K. Inouye elected to Institute of Medicine 2Health News:It's Easy to Mistake Medicine for Candy 2Health News:It's Easy to Mistake Medicine for Candy 3Health News:Obese women have higher risk of suffering breast cancer 2Health News:Many Don't Believe Their Obesity is Unhealthy: Study 2Health News:Many Don't Believe Their Obesity is Unhealthy: Study 3Health News:Many Don't Believe Their Obesity is Unhealthy: Study 4Health News:Profanity on TV Linked to Foul-Mouthed Kids 2
(Date:9/18/2014)... LONDON , September 18, 2014 ... supply chain community, we,re finally here - the new programme ... in January 2015, part of our global Cool Chain series, ... agenda here ! As the lines between ... have put together a programme that is broad and yet ...
(Date:9/18/2014)... 2014 Relmada Therapeutics, Inc., (OTCQB: RLMD), a ... chronic pain, announced today that it has appointed Mr. ...  Senior Director of Clinical Development. During his ... and led successful global clinical operations teams, in the ... the clinical development of numerous therapeutics and diagnostics across ...
(Date:9/18/2014)... Sept. 18, 2014   Regulus Therapeutics Inc ... company leading the discovery and development of innovative ... its ATHENA natural history of disease study in ... disease with no approved therapy. The ATHENA study ... renal function markers such as Glomerular Filtration Rate ...
Breaking Medicine Technology:Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6
... for Candida albicans in only five ... two enzyme color reactions to produce ... read. AlbiQuicktm is performed on a ... Incubation time is only five minutes ...
... for small and large multi-specialty provider networks. ... check-out. Review the complete Patient History, from ... labs and charts all by one click ... immediately. Communicate electronically with the referring physicians ...
... meridianEMR is a revolutionary "blended model EMR ... medical records in your office and on-line ... of physicians and software engineers, meridianEMR combines ... create a highly modular medical EMR that ...
... an Automated Digital Cell Morphology and Informatics ... and transmission of White & Red Blood ... blood smears can be loaded at once, ... 60 per hour depending on the tests ...
Medicine Products: